The following analysts have issued research coverage on Protox Therapeutics. The opinions, estimates or forecasts regarding Protox's performance made by analysts are theirs alone and do not necessarily represent the opinions, forecasts or predictions of Protox or its management. Protox does not by its reference below or distribution imply its endorsement of or concurrence with such opinions, estimates or forecasts.

Byron Capital Markets
Douglas W. Loe, Ph.D., MBA
Email: DLoe@byroncapitalmarkets.com
Tel: (647) 426-0472

What's New

December 28, 2011
Protox Therapeutics Announces Closing of Additional CDN $8.3M Investment By Warburg Pincus

December 23, 2011
Protox Therapeutics Announces Additional CDN $8.3M Investment by Warburg Pincus

December 22, 2011
Protox Completes Dosing of Second Cohort of Patients in Transrectal Study

Events

November 17, 2010
- 11:15 am ET
Protox Presents at Dundee Emerging Growth Conference

Stock Quote

	LAST TRADE:	$0.35
	TRADE TIME:	3:49PM EST
	CHANGE:	$0.02 (6.06%)
	PREV CLOSE:	$0.33
	OPEN:	$0.335
	BID:	$0.34
	ASK:	$0.35